Last reviewed 2026-04-20 · How we verify

Carbochloral (CARBOCLORAL)

Phase 2 active Small molecule

Carbochloral (generic name: CARBOCLORAL) is a drug. It is currently in Phase 2 development.

Carbochloral is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.

Carbochloral is a small molecule compound with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. The compound's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Further research is needed to determine its potential therapeutic applications and safety profile. As a result, it is not currently available as a prescription medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CARBOCLORAL
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and the key to unlocking a specific lock is a molecule that fits perfectly. Carbochloral is like a key that binds to a specific lock, or target, in the body, which can help to restore balance and prevent disease. This binding action can trigger a series of downstream effects that ultimately lead to the desired therapeutic outcome.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carbochloral CI brief — competitive landscape report
Carbochloral updates RSS · CI watch RSS

Frequently asked questions about Carbochloral

What is Carbochloral?

Carbochloral (CARBOCLORAL) is a Small molecule drug.

How does Carbochloral work?

Carbochloral is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Carbochloral?

CARBOCLORAL is the generic (nonproprietary) name of Carbochloral.

What development phase is Carbochloral in?

Carbochloral is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing